Search - tctmd.com

Displaying 1 - 20 of 88

Sort: Relevancy | Date

Presentation ESC 2025

Vericiguat in ambulatory patients with chronic heart failure with reduced ejection fraction: Results of the VICTOR trial

Presenter: Faiez Zannad

August 30, 2025

Presentation ESC 2025

DAPA ACT HF – TIMI 68: Dapagliflozin in Patients Hospitalized for Heart Failure

Presenter: David D. Berg

August 30, 2025

Presentation TCT India 2025

Role of Vericiguat in Worsening Heart Failure

Presenter: J.P.S. Sawhney

July 26, 2025

Presentation ACC 2025

Dapagliflozin after Transcatheter Aortic Valve Implantation

Presenter: Sergio Raposeiras-Roubin

March 29, 2025

Presentation THT 2025

Use of AI for Improved HF Event Detection and Automated Drug Titration in Patients With and RPM Deice Planning for the Future: Perspective 1

Presenter: Harry Rowland

February 13, 2025

Presentation THT 2025

Use of AI for Improved HF Event Detection and Automated Drug Titration in Patients With and RPM Deice Planning for the Future: Perspective 2

Presenter: Kartik Sundareswaran

February 13, 2025

Presentation THT 2025

Safety and Feasibility of Renal Venous Afterload Modulation With the Doraya in Acute Decompensated Heart Failure and Persistent Congestion From Insufficient Response to Diuretic Therapy

Presenter: Lucas Zier

February 13, 2025

Presentation THT 2025

Drugs Are All I Need to Treat This, and a Vast Majority of Patients

Presenter: Lynne Stevenson

February 12, 2025

Presentation THT 2025

Impact of HF Pharmacological Therapy on the Durability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis

Presenter: Stavros Drakos

February 12, 2025

Presentation THT 2025

Assessing Long-Term Outcomes of Tirzepatide and Semaglutide in Heart Failure With Preserved Ejection Fraction: A Retrospective Cohort Analysis From TrinetX Database

Presenter: Thitiphan Srikulmontri

February 12, 2025

Presentation THT 2025

Proactive Medical Management: GDMT & Diuretic Strategies Based on PA Pressure, Vital Signs, and Symptoms

Presenter: Michael Kiernan

February 12, 2025

Presentation THT 2025

Rationale for Mineralocorticoid Receptor Blockade with Finerenone in HF

Presenter: Carolyn Lam

February 12, 2025

Presentation THT 2025

The HF Physician's Approach: GDMT - Give the Darn Medicines a Try!

Presenter: Ryan Tedford

February 12, 2025

Presentation THT 2025

Medical Management (Heparin/ Lytics)

Presenter: Gregory Piazza

February 12, 2025

Presentation THT 2025

DOACS in LVAD: Should We, Should We Not?

Presenter: Palak Shah

February 12, 2025

Presentation THT 2025

When and Why Are Diuretics Sometimes Just Not Enough?

Presenter: Jennifer Cowger

February 12, 2025

Presentation THT 2025

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 12, 2025

Presentation THT Abstracts 2025

Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Subcutaneous (SC) Injection of a Novel-Formulation of Furosemide (FUR) Administered via an Autoinjector

Presenter: John Mohr

February 11, 2025

Presentation THT Abstracts 2025

Impact of HF Pharmacological Therapy on the Durability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis

Presenter: Stavros Drakos

February 11, 2025

Presentation THT 2025

Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Subcutaneous (SC) Injection of a Novel-Formulation of Furosemide (FUR) Administered via an Autoinjector

Presenter: John Mohr

February 11, 2025

Advertisement

Vericiguat in ambulatory patients with chronic heart failure with reduced ejection fraction: Results of the VICTOR trial

DAPA ACT HF – TIMI 68: Dapagliflozin in Patients Hospitalized for Heart Failure

Role of Vericiguat in Worsening Heart Failure

Dapagliflozin after Transcatheter Aortic Valve Implantation

Use of AI for Improved HF Event Detection and Automated Drug Titration in Patients With and RPM Deice Planning for the Future: Perspective 1

Use of AI for Improved HF Event Detection and Automated Drug Titration in Patients With and RPM Deice Planning for the Future: Perspective 2

Safety and Feasibility of Renal Venous Afterload Modulation With the Doraya in Acute Decompensated Heart Failure and Persistent Congestion From Insufficient Response to Diuretic Therapy

Drugs Are All I Need to Treat This, and a Vast Majority of Patients

Impact of HF Pharmacological Therapy on the Durability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis

Assessing Long-Term Outcomes of Tirzepatide and Semaglutide in Heart Failure With Preserved Ejection Fraction: A Retrospective Cohort Analysis From TrinetX Database

Proactive Medical Management: GDMT & Diuretic Strategies Based on PA Pressure, Vital Signs, and Symptoms

Rationale for Mineralocorticoid Receptor Blockade with Finerenone in HF

The HF Physician's Approach: GDMT - Give the Darn Medicines a Try!

Medical Management (Heparin/ Lytics)

DOACS in LVAD: Should We, Should We Not?

When and Why Are Diuretics Sometimes Just Not Enough?

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Subcutaneous (SC) Injection of a Novel-Formulation of Furosemide (FUR) Administered via an Autoinjector

Impact of HF Pharmacological Therapy on the Durability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis

Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Subcutaneous (SC) Injection of a Novel-Formulation of Furosemide (FUR) Administered via an Autoinjector

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content